Abstract: A powder comprises one or more monoclonal antibody, one or more cyclodextrin, and a compound selected from carboxymethyl dextran (CMD), one or more basic amino acid, or both. The powder may be compressed to form a compressed shape such as minitabs. A method of forming a powder comprises the steps of: 1) providing one or more monoclonal antibody, one or more cyclodextrin, and a compound selected from carboxymethyl dextran (CMD), one or more basic amino acid, or both; 2) forming a solution comprising the monoclonal antibody, cyclodextrin, CMD, and amino acid; and 3) drying the solution. This complexed mAb was found to be stable in resisting aggregation during the process of evaporative solidification and compression at pressures up to 10.5 kbar. Also, the complexed mAb has more resistance towards proteolysis than that of uncomplexed mAb.